AGP Executive Report
Last update: 7 hours agoDrug Safety & Policy: A U.S. House committee is investigating major pharma companies (Pfizer, Merck, AbbVie, Eli Lilly, Bristol Myers Squibb) over clinical trials at China’s military-linked hospitals and in Xinjiang, raising questions about consent and security risks. Cancer Care: GSK says its B7-H3–targeted antibody-drug conjugate Risvutatug rezetecan improved overall survival versus topotecan in a phase 3 relapsed/advanced small cell lung cancer trial, supporting a China submission. Youth Mental Health: A new live-in program, Step Up Step Down, is set to open in Greater Sudbury for youth ages 12–17, combining on-site schooling with intensive mental health support. Insurance & Access: CVS/Aetna’s CEO says GLP-1 coverage hinges on prices dropping and stronger proof that higher upfront costs lead to downstream savings. Public Health & Environment: Health Canada will allow drones to apply already-approved pesticides, aiming for more precise, targeted crop protection. Healthcare Tech: Concord Technologies and the American Hospital Association highlight how AI can speed interoperability and reduce manual document processing. Workplace Wellness: A heated yoga trial analysis links more sessions with lower depression severity, pointing to a scalable non-drug option.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
